Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype.

Journal of visualized experiments : JoVE - 17 Jun 2022

Das Saswati, Stallon Illangeswaran Raveen Stephen, Ijee Smitha, Kumar Sanjay, Velayudhan Shaji Ramachandran, Balasubramanian Poonkuzhali

Abstract excerpt

Understanding clinically relevant driver mechanisms of acquired chemo-resistance is crucial for elucidating ways to circumvent resistance and improve survival in patients with acute myeloid leukemia (AML). A small fraction of leukemic cells that survive chemotherapy have a poised epigenetic state to tolerate chemotherapeutic insult. Further exposure to chemotherapy allows these drug persister cells to attain a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytarabine
Share to Drug Resistance

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Phenotype

Share to RNA, Small Interfering

Source

Open in PubMed Open full text

Identifiers

PMID: 35786700
DOI: 10.3791/63383
PMCID: PMC7614927

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype.PMID 35786700Read ↗

Dynamic heterogeneity towards drug resistance in AML cells is primarily driven by epigenomic mechanism unveiled by multi-omics analysisSemantic proximity Read ↗

The contributing factors of resistance or sensitivity to epigenetic drugs in the treatment of AML.Semantic proximity Read ↗

Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.Semantic proximity Read ↗

Patient-tailored design of AML cell subpopulation-selective drug combinationsSemantic proximity Read ↗

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AMLSemantic proximity Read ↗

Drug resistance, epigenetics, and tumor cell heterogeneity.Semantic proximity Read ↗

SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells.Semantic proximity Read ↗

Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML.Semantic proximity Read ↗

shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.Semantic proximity Read ↗

Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy.Semantic proximity Read ↗

Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemiaSemantic proximity Read ↗

Characterization of Newly Established Pralatrexate-resistant Cell Lines and the Mechanisms of ResistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.